✦ LIBER ✦

Reduction in Receptors for Bombesin and Epidermal Growth Factor in Xenografts of Human Small-Cell Lung Cancer after Treatment with Bombesin Antagonist RC-3095

✍ Scribed by Gabor Halmos and Andrew V. Schally

Book ID: 123640421
Publisher: National Academy of Sciences
Year: 1997
Tongue: English
Weight: 844 KB
Volume: 94
Category: Article
ISSN: 0027-8424
DOI: 10.2307/41417

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bombesin/gastrin-releasing peptide antag

Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma

✍ Miklós Koppán; Gábor Halmos; José M. Arencibia; Najib Lamharzi; Andrew V. Schall 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 1 views

## BACKGROUND. Antagonists of bombesin/gastrin-releasing peptide (BN/GRP) have been developed to block the autocrine stimulatory effect of BN/GRP on tumors such as small cell lung carcinoma (SCLC). Although several studies have addressed the intracellular events that follow the formation of the re

Inhibition of growth of MKN45 human gast

Inhibition of growth of MKN45 human gastric-carcinoma xenografts in nude mice by treatment with bombesin/gastrin-releasing-peptide antagonist (RC-3095) and somatostatin analogue RC-160

✍ Jucek Pinski; Gabor Halmos; Tetsu Yano; Karoly Szepeshazi; Yunfeng Qin; Tibor Er 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 French ⚖ 853 KB

## Abstract Nude mice bearing xenografts of the gastrin‐responsive human gastric carcinoma MKN45 cell line were treated for 4 to 5 weeks with bombesin/gastrin‐releasing‐peptide(GRP) antagonist (RC‐3095), somatostatin analogues RC‐160 and SMS 201‐995, or the combination of RC‐3095 and RC‐160. Tumor

Mutations of the Epidermal Growth Factor

Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non-Small-Cell Lung Cancer With Postoperative Recurrence

✍ Mitsudomi, T. 📂 Article 📅 2005 🏛 American Society of Clinical Oncology 🌐 English ⚖ 261 KB

SAA1 is over-expressed in plasma of non

SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors

✍ Milan, Enrico; Lazzari, Chiara; Anand, Santosh; Floriani, Irene; Torri, Valter; 📂 Article 📅 2012 🏛 Elsevier 🌐 English ⚖ 791 KB

Do We Really Need Another Epidermal Grow

Do We Really Need Another Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in First-Line Treatment for Patients With Non-Small-Cell Lung Cancer and EGFR Mutations?

✍ Haspinger, E. R.; Garassino, M. C.; Torri, V.; Cinquini, M.; De Braud, F.; Gelso 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 78 KB

Antitumor activity of the epidermal grow

Antitumor activity of the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 (‘lressa’), alone or combined with gemcitabine and vinorelbine platinum-based chemotherapy, in human non-small-cell lung cancer (NSCLC) xenografts

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 132 KB